

# Index

- AACAP Guidelines for Use of ECT with Adolescents, 67, 69
- abdominal aortic aneurysm, 249
- Aberrant Behaviour Checklist, 50
- ablative neurosurgery, 10, 144–46
- depression, 145–46
- outcome studies, 145
- technical aspects, 145
- accreditation. *See* Scottish ECT Accreditation Network (SEAN), *See* ECT Accreditation Service (ECTAS)
- acetylcholinesterase inhibitors, 225, 228
- adolescence. *See also* paediatric ECT
- consent and, 70, 260
- guidelines for use of ECT, 67, 69
- intellectual disability and, 55
- Adults with Incapacity (Scotland) Act 2000, 260–62
- advance statements, 263
- adverse effects of ECT
- cardiovascular, 206
- cognitive. *See* cognitive side effects of ECT
- memory. *See* memory impairment
- musculo-skeletal, 206
- non-cognitive, 121–26
- schizophrenia, 80
- affective network, 14
- agitation, 207
- alfentanil, 204
- alpha-methyl-para-tyrosine (AMPT), 18
- Alzheimer's disease, 46
- amino acid neurotransmitters, 14
- amnesia. *See* memory impairment
- anaesthesia, 202–7
- commonly used drugs, 219
- dental issues, 214
- induction agents. *See* induction agents
- investigations, 203
- issues, 187
- lead anaesthetist role in, 202
- monitoring, 203
- patient evaluation, 202
- practice guidelines, 202
- pregnancy and, 64
- aneurysm, 249
- anterograde amnesia, 109, 111
- anticholinergics, 206, 219
- anticoagulation, 248
- anticonvulsants, 98, 195
- interactions with ECT, 223, 227
- antidepressants, 3, *See also* ketamine
- effectiveness vs. ECT, 15
- epilepsy and, 99
- functional imaging studies, 16
- inflammation and, 17
- interactions with ECT, 221, 226
- mechanism of action, 151–52
- older adults, safety issues, 45
- post-ECT relapse and, 27
- serotonin/noradrenaline effect, 18
- anti-inflammatories, 15
- anti-NMDAR encephalitis, 102
- antipsychotics, 75, *See also* clozapine
- interactions with ECT, 223, 226
- resistance to, 68
- anxiety, 155
- anxiolytics, 224, 228
- APR position statement, ketamine, 156
- assessment
- autobiographical amnesia, 114–15
- before ECT, 121
- capacity, 256–57
- cognitive, 3, 113–15, 117, 186
- atracurium, 205
- audit, 6, 8, 268
- autism, 53–55
- autobiographical amnesia, 13, 41, 109, 112–13
- assessment, 114–15
- Autobiographical Memory Interview, 115
- autoimmune disorders, 102
- automatic implanted cardioverter defibrillator (AICD), 248
- benzodiazepines, 16
- catatonia, 86, 90–92, 100
- interactions with ECT, 228
- older adults, 46
- best interests, 257
- beta-blockers, 206
- BFCRS score, 89
- bifrontal ECT, 34, 189–90
- catatonia, 89
- electrode placement, 78
- bilateral ECT, 188
- catatonia, 89
- electrode placement, 78
- emergency treatment, 28
- mania, 34
- vs. unilateral, 190
- vs. unilateral in depression, 2, 15, 25
- bipolar disorder, 4, 32, *See also* mixed affective episodes, *See also* mania
- catatonia with, 87
- pregnancy and, 5
- bipolar disorder depression, 4, 38–41
- cognitive side effects of ECT, 41
- efficacy of ECT, 38–40
- general treatment principles, 40–41
- recommendations, 41
- relapse rates, 41
- switch to mania, treatment and, 40, 124
- timing of ECT usage, 39
- bite-guards, 204, 213, 215
- bitemporal ECT, 34, 188
- catatonia, 89

- efficacy in older adults, 44  
 electrode placement, 78  
 bladder effects, ketamine, 154  
 blood glucose levels, 187  
 bradycardia, 64, 193, 205, 247  
 brain  
   networks within, 13  
   tumours, 249  
 brain derived neurotrophic factor (BDNF), 14–15  
 brain imaging, 13–16, *See also*  
   magnetic resonance imaging (MRI)  
   functional, 16  
   structural, 15–16  
 breastfeeding, 65  
 brief pulse (BP) ECT, 26, 191  
 bupropion, 18, 226  
  
 caffeine, 194  
 camphor, 74  
 capacity, 254  
   assessing, 256–57  
   definition, 256  
   paediatric ECT, 70  
   schizophrenia patients, 80  
 capacity legislation, 257–65  
   England and Wales, 257–60  
   Northern Ireland, 264–65  
   Republic of Ireland, 265–66  
   Scotland, 260–64  
 capnography, 183  
 capsulotomy, 10, 145  
 carbamazepine, 227  
 cardiac arrhythmia, 64, 206  
 cardiac failure, 249  
 cardiac pacemakers, 248  
 cardiovascular disease, 45–46,  
   123–24, 218, 248–49  
 cardiovascular response, 236  
 cardiovascular side effects, 154,  
   206  
 carers  
   education/information  
     provision, 173–74  
   experience of ECT, 270  
   information for, 58  
   support from nurses, 176  
   views on paediatric ECT, 71  
 catatonia, 85–93, 100–1  
   classification and diagnosis,  
     85–86  
   co-administration of  
     benzodiazepines, 90–91  
   continuation/maintenance  
     treatment, 91  
   current usage of ECT, 86  
   duration of ECT treatment,  
     90  
   efficacy and effectiveness of  
     ECT, 87–89  
   electrode placement, 89, 92  
   frequency of ECT, 89  
   history of, 86  
   intellectual disability and,  
     53–55  
   NICE guidelines, 5, 86  
   NMS and, 101  
   paediatric ECT, 69  
   recommendations for ECT, 92  
   types of, 53  
 Catatonia Rating Scales, 53  
 cellular pathology, 14  
 cerebral aneurysm, 249  
 cerebral tumours, 249  
 cerebrovascular disease, 249  
 challenging behaviour, 55–56  
 checklist for ECT treatment,  
   178, 187  
 chemically induced seizures, 74  
 childhood. *See also* paediatric  
   ECT  
   intellectual disability and, 55  
 chlorpromazine, 75, 77  
   mania treatment, 32–33  
 cholinesterase inhibitors, 46  
 cingulotomy, 10, 145  
 Clinical Global Impression  
   (CGI) scores, 102  
 clinical governance, 6, 181  
 clozapine, 68  
   adverse effects, 80  
   catatonia, 101  
   ECT augmentation, 77  
   psychosis in Parkinson's  
     disease, 97  
   treatment resistance to, 81  
 cochlear implants, 250  
 coercion, 255, 268  
 cognitive assessment, 113–15,  
   117, 186  
   in depression, 3  
 cognitive control network, 14  
 cognitive impairment, 2  
   dementia with ECT, 103  
   ketamine, 153  
 cognitive side effects of ECT,  
   109–17, 207  
   bilateral vs. unilateral, 25  
   bipolar disorder depression,  
     41  
   immediate, 110–11  
   prevention, 115–16  
   subacute and longer term,  
     111–13  
   types of, 109  
 compulsory treatment order,  
   259, 262–63  
 consent  
   before ECT, 121  
   dental risks and, 212–13  
   informal patients, 260  
   informed, 2, 260  
   intellectual disability and, 58  
   paediatric ECT, 70, 260  
   rTMS, 6  
   seeking, 254–56  
   written, 255  
 continuation ECT, 27, 197  
   catatonia, 91  
   schizophrenia, 79–81  
 cortex, 13  
 cortical connectivity, 16  
 Court of Protection, 257, 259  
 C-Reactive Protein (CRP), 15  
 cuff technique, 234, 236, 251  
  
 deep brain stimulation (DBS),  
   10, 140, 143–44  
 default mode network, 13, 16  
 delirium, 102–3, 111  
 delta activity, 239  
 delusions, 27  
 dementia, 102–3  
   behavioural disturbance  
     with, 102  
   depression with, 103  
   ECT challenges, 46  
   psychosis with, 103  
 dental issues, 211–16  
   bite-guards, 204, 213, 215  
   bridges, 214  
   crowns, 214  
   dentures, 216  
   for anaesthetists, 214  
   implants, 215  
   intraosseous dental supports,  
     215  
   risk management strategy,  
     212–14  
   veneers, 214  
 depression, 24–29, *See also*  
   bipolar disorder  
   depression, *See also*  
   antidepressants  
   ablative neurosurgery, 145–46  
   bipolar disorder, 4, 38–41  
   capacity and, 256

- depression (cont.)  
 DBS, 144  
 dementia, 103  
 different populations, 28  
 efficacy of ECT treatment, 24–26  
 emergency treatment with ECT, 28  
 epilepsy and, 99  
 ketamine treatment, 7–8  
 memory impairment and, 114  
 NICE guidelines on ECT usage, 2–3  
 NMD treatment, 9  
 older adults, 44  
 Parkinson's disease and, 97  
 pathophysiology of, 13–15  
 predictors of response to ECT, 27  
 pregnancy, 5, 63–64  
 RCP position statement, 3  
 relapse, post-ECT, 27–28  
 rTMS, 6, 130  
 single neurotransmitter theories of, 13  
 tDCS treatment, 8–9  
 treatment-resistant, 28, 131, 149  
 types that respond to ECT, 27  
 unilateral vs. bilateral ECT, 2, 15, 25  
 VNS, 143  
 vs. schizophrenia ECT usage, 75  
 detained patients, 70, 261, 264–65  
 diabetes, 250  
 diazepam, 194  
 disorientation, 110  
 dopamine antagonists, 99  
 dose of electrical stimulus, 25  
 Down syndrome, 57  
 drug abuse/dependence, 153  
 drug interactions with ECT, 218–29  
   by drug class, 221  
   types of evidence used, 220  
 eating disorders, 155  
 ECT Accreditation Service (ECTAS), 67, 75, 161–63, 171, 202, 268  
   Standards, 161, 168, 178  
 ECT clinics  
   inspection, 161–62  
   managing, 179–80  
   nurse-administered ECT, 180  
   service delivery, 168–69  
   service standards, 171  
 ECT treatment suite, 183–85  
   capacity assessment, 256  
   equipment, 183–84  
   nursing care in the, 177–78  
   rationalisation and closure, 184–85  
   treatment room, 183  
   waiting area, 183  
 EEG monitoring, 237–45  
   artefacts, 244  
   electrode placement, 237  
   establishing a baseline EEG, 238  
   ictal and postictal phases, 239–44  
   electrical current, dosage of, 15  
   electrically induced seizures, 75  
   electrocardiography (ECG), 203, 244  
   electrode artefact, 244  
   electrode placement, 188–90, 237  
     bilateral vs. unilateral, 78  
     catatonia, 89, 92  
     mania, 34  
   electrodecremental phase, 239  
   electromyography (EMG), 235  
   emergency treatment, 28, 259  
   encephalitis, 102, 249  
   epilepsy, 74–75, 98–99, 141  
   esketamine, 150–51  
   esmolol, 206  
   ethics, 9, 57  
   etomidate, 195, 205  
   falls, 125  
   families. *See* carers  
   fentanyl, 204  
   first-line treatment  
     depression with ECT, 29  
     ECT as, 3  
   flumazenil, 90  
   flupentixol, 79  
   frequency of ECT, 26, 69, 78, 89, 92, 186  
   functional MRI (fMRI), 13, 16, 129  
   gamma-aminobutyric acid (GABA), 14, 16–17, 85  
   glaucoma, 206, 251  
   glutamate, 14, 16–17, 85, 151  
   glycopyrrolate, 206  
   grimacing, 193, 211  
 Hamilton cuff technique, 234, 236, 251  
 Hamilton Depression Rating Scale (HDRS), 24, 196  
 herpes simplex virus, 102  
 hippocampus, 15–16, 19  
 Huntington's disease, 100  
 hyperventilation, 46, 194, 204  
 hypnotics, 224, 228  
 ictal EEG phases, 239–44  
 impaired executive function, 109, 112  
 impedance, measuring, 191  
 implanted pulse generator (IPG), 140–41  
 incident mania, 34  
 induction agents, 90, 204, 219  
 inflammation, 15  
   ECT and, 17  
 informal patients, 254–56, 260  
 information  
   different formats, 173  
   different sources of, 255  
   for carers, 58  
   nurses as a resource for, 173  
   sharing with the patient, 254–55  
 informed consent, 2, 260  
 intellectual disability, 50–59  
   autism and catatonia, 53–55  
   case series/reports, 51, 53, 55–56  
   challenging behaviour and, 55–56  
   diagnostic issues, 50  
   mood disorders and, 51–53  
   observations on the use of ECT, 56–57  
   prevalence of psychiatric disorders, 51  
   recommendations, 58  
   self-injurious behaviour, 68  
   syndromes associated with, 56  
 interleukin-6 (IL-6), 15, 17  
 intracranial foreign objects, 250  
 Irish Mental Health Act 2001, 265  
 ketamine, 7–8, 17, 149–57, 205  
   clinical effects, 149–50

- clinics and guidance, 155  
 ECT and, 152  
 formulations and licensing, 154–55  
 glutamate and, 14  
 registries and monitoring, 156  
 side effects, 7, 152–54
- Lasting Power of Attorney, 257–58
- lead consultant, 168–69, 185
- lesion neurosurgery. *See* ablative neurosurgery
- Lewy Body Dementia, 46
- lipopolysaccharide (LPS), 17
- lithium, 3  
   cognitive side effects, 110  
   interactions with ECT, 223, 227  
   vs. ECT in mania treatment, 32–33
- lorazepam, 53, 55, 86, 91
- MADRS (Montgomery-Asberg Depression Rating Scale), 167
- magnetic resonance imaging (MRI), 13–14, 16, 130
- maintenance ECT, 28, 197  
   catatonia, 91  
   schizophrenia, 80
- malignant catatonia, 86, 88–89, 92, 101
- malignant hyperthermia, 204
- mania, 4  
   ECT and concomitant medication, 34  
   efficacy of ECT treatment, 32–33  
   electrode placement and stimulation parameters, 34  
   incident to ECT treatment, 34  
   recommendations for ECT, 35  
   side effect of ECT, 124  
   switch to bipolar depression, treatment and, 40  
   mechanism of action of ECT, 13–19
- memory impairment  
   adolescents, 69  
   anterograde amnesia, 109, 111  
   autobiographical, 13, 41, 109, 112–15  
   patients' experience of, 268
- Mental Capacity Act (Northern Ireland) 2016, 70, 264
- Mental Capacity Act 2005, 58, 257–65
- Mental Health (Care and Treatment) (Scotland) Act 2003, 260, 262
- Mental Health (Northern Ireland) Order (1986), 264
- Mental Health Act 1983, 258–59  
   mental capacity, 80  
   paediatric ECT, 70  
   methohexital, 195, 205  
   mirtazapine, 24, 194, 226  
   mivacurium, 205
- mixed affective episodes  
   ECT and concomitant medication, 34  
   efficacy of ECT, 33  
   recommendations for ECT, 35
- monitoring  
   anaesthesia, 203  
   ECT, 186  
   EEG, 237–45  
   ketamine, 156  
   post-ECT, 195–97  
   seizures, 234–45
- monoamine oxidase inhibitors (MAOIs), 222, 226
- monoamines, 18–19
- Montgomery-Åsberg Depression Rating Scale (MADRS), 38
- mood disorders, 68  
   intellectual disability, 51–53
- Mood, Interest and Pleasure Questionnaire (MIPQ), 50
- mortality rate, 121–23
- movement artefact, 244
- movement disorder, 96–97, 103
- multiple sclerosis, 101
- muscle artefact, 244
- muscle relaxants, 192, 204, 234
- musculo-skeletal side effects, 206
- myocardial infarction, 248
- neuroleptic malignant syndrome (NMS), 69, 86, 101
- neuromodulation, 140
- neuropsychiatric disorders, 96–104
- neurosurgery for mental disorder (NMD), 9–11, 140–46
- neurotransmitters, 14
- neurotrophic hypothesis, depression, 14
- NICE guidelines  
   antenatal and postnatal mental health, 5  
   bipolar disorder, 4  
   challenging behaviour and learning disability, 56  
   cognitive assessment, 186  
   ECT, 161  
   ECT in catatonia, 5, 86  
   ECT in depression, 2–3  
   ECT in pregnancy, 63  
   ECT in schizophrenia, 75  
   rTMS, 6, 130, 135  
   schizophrenia, 4  
   tDCS for depression, 8  
   VNS, 11, 143
- NICE Technology Appraisal 2003, 4, 267
- NMD (neurosurgery for mental disorder), 9–11, 140–46
- N-methyl-D-aspartate (NMDA) receptor, 14, 151
- NMS (neuroleptic malignant syndrome), 69, 86, 101
- non-cognitive side effects of ECT, 121–26  
   assessment before, 121  
   cardio-pulmonary, 123–24  
   mania, 124  
   mortality rate, 121–23  
   prevalence of, 125  
   prolonged seizures, 124  
   suicide, 124
- non-memory cognitive side effects, 111–12
- noradrenaline, 18
- nortriptyline, 24
- number of ECT treatments, 26, 196–97
- nursing, 173–81  
   administered ECT, 180  
   clinical governance, 181  
   ECT lead nurse, 163  
   ECT nurse specialist, 179–80  
   ECT treatment suite, 177–78, 185  
   education/information role, 173–74  
   inpatients and day patients, 173–74  
   preparing patient for ECT, 177  
   recovery care, 178

- nursing (cont.)  
 supportive role, 176  
 theatre environment, 179  
 training and development, 180
- obsessions, 98
- obsessive-compulsive disorder (OCD)  
 DBS treatment, 143  
 ketamine, 155  
 NMD treatment, 9
- oesophageal reflux, 250
- older adults, 44–47  
 efficacy of ECT, 44–45  
 practical considerations, 46  
 recommendations for ECT, 47  
 rTMS in, 134  
 safety issues, 45–46
- optical motor sensor (OMS), 236
- organic catatonia, 100
- osteoporosis, 251
- paediatric ECT, 67–71  
 catatonia, 69  
 consent, capacity and legal considerations, 70–71, 260  
 epidemiology, 67  
 indications for use, 67–68  
 mood disorders, 68  
 NMS, 69  
 patients, carers and clinicians views, 71  
 prognosis, 70  
 psychotic disorders, 68  
 side effects, 69–70
- Parkinson's disease, 18, 96–98, 143, 249
- patients  
 anaesthetic evaluation, 202  
 detained, 70, 261, 264–65  
 experience of rTMS, 134  
 incapable of informed consent, 260  
 informal, 254–56, 260  
 information/education provision, 173–74  
 inpatient and day patient care, 174–76  
 patient-centred services, 165  
 perspectives of ECT, 267–70  
 preparation for ECT, 177  
 recovery care and discharge, 178
- selection for rTMS, 131–32  
 support from nurses, 176  
 views on paediatric ECT, 71
- pentylentetrazol, 74
- pharmacotherapy. *See also individual drug groups, See also drug interactions with ECT*  
 anaesthetics commonly used, 219  
 relapse post-ECT and, 27  
 vs. ECT in bipolar depression, 38–39  
 vs. ECT treatment, 33  
 physiological effects of ECT, 206
- polyspike activity, 239
- Positive Behaviour Support, 56
- positron emission tomography (PET), 15
- post-ictal delirium, 102, 111
- post-ictal suppression, 243
- postnatal period, 63  
 ECT in the, 64–65  
 key points, 65
- post-traumatic stress disorder (PTSD), 155
- predictors of response to ECT, 27
- prefrontal cortex, 14
- pregnancy, 63–64  
 ECT during, 5, 63–64  
 key points, 65  
 rTMS in, 134
- prescribing ECT, 186
- propofol, 69, 90, 205, 207
- puerperal psychosis, 64
- pulmonary disease, 123–24, 248
- pulse width, 26, 191
- quinolinic acid, 17
- RCP Best Practice Guide to ECT Training, 168–70
- RCP Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities, 50
- RCP position statement  
 ECT in depression, 3, 29  
 ketamine, 7, 156  
 NMD, 9, 144–45  
 tDCS treatment, 9
- recruiting rhythm, 239
- relapse  
 bipolar disorder depression, 41  
 post-ECT, 27–28, 197
- remifentanyl, 204, 219
- remission rates, 27, 196
- repetitive TMS (rTMS), 6, 129–36  
 administration, 132–33, 135  
 administration, training for, 134–36  
 contraindications, 131  
 efficacy in depression, 130  
 guidance and approvals, 130  
 patient selection, 131–32  
 patients' experience of, 134  
 safety, 133  
 vs. ECT, 132  
 vs. ECT in depression, 25
- resting motor threshold (RMT), 133
- resting state fMRI, 13
- resting state network connectivity, 16
- retrograde amnesia. *See autobiographical amnesia*
- risk-benefit analysis, 251
- risperidone, 87
- rocuronium, 206
- safety  
 guidance pre-surgery, 178  
 older adults and, 45–46  
 rTMS, 133, 136
- schizophrenia, 74–82  
 adverse effects and risks of ECT, 80  
 continuation ECT, 79–81  
 current ECT usage, 75  
 duration of acute treatment, 78–79  
 ECT recommendations, 81  
 efficacy and effectiveness of ECT, 75–77  
 electrode placement, 78  
 frequency of treatment, 78  
 history of treatment, 74–75  
 intellectual disability and, 57  
 legal considerations of ECT, 80  
 maintenance ECT, 80  
 NICE guidelines, 4  
 speed of response to ECT, 77  
 treatment-resistant, 4, 76, 81

- Scottish ECT Accreditation Network (SEAN), 161, 164–67, 170–71  
 patient-centred, 165  
 Standards, 165  
 second opinion doctors, 70, 80, 258  
 second-line treatment  
   depression with ECT, 29  
   ECT as, 3  
 seizure monitoring, 234–45, *See also* EEG monitoring  
   adequacy of seizure, 245–46  
   cardiovascular response, 236–46  
   motor activity, 234–36  
 seizure threshold, 190  
   definition, 192  
   establishing, 192–94  
   measurement, 192  
   too high, 194  
 seizures, 98, *See also* epilepsy  
   adequacy of, 195  
   adolescents, 69  
   chemically induced, 74  
   ECT effectiveness and, 15, 191–92  
   ECT in depression, 16  
   electrically induced, 75  
   older adults, 45–46  
   prolonged, 124, 195  
   termination, 241  
   too short, 195  
 selective serotonin reuptake inhibitors (SSRIs), 221, 226  
 self-injurious behaviour, 55, 68, 91  
 serotonin (5-HT), 18  
 serotonin and noradrenergic reuptake inhibitors (SNRIs), 221, 226  
 service delivery, 168–69  
 service standards, 171  
 Service User Research Enterprise (SURE), 267–68  
 sevoflurane, 204  
 short-term detention certificate (STDC), 262–63  
 sine wave ECT, 26  
 smoking, 45  
 staffing, 185–86, *See also* nursing, *See also* lead consultant  
 standardised Mini Mental State Exam (sMMSE), 113  
 status epilepticus, 99  
 stigma, ECT, 173  
 stimulation parameters, 34  
 stimulus dosing, 191–95  
   protocol, 193  
 stimulus titration, 192  
 stroke, 100, 249  
 Subjective Memory Assessment, 113  
 subjective memory difficulty, 109, 113  
 suicide, 124  
   ECT efficacy, 27  
   ketamine effect on, 150  
   schizophrenia, 81  
 sulpiride, 77  
 suxamethonium, 204, 206  
 systemic lupus erythematosus (SLE), 100  
 tardive dyskinesia, 103, 250  
 theophylline, 194, 229  
 theta activity, 239  
 thiopental, 205  
 tonic-clonic seizure, 191  
 training course, rTMS, 134–35  
   administration, 135  
   efficacy and safety, 136  
   setting up the machine, 135  
 training, nursing, 180  
 training, psychiatrists, 168–71  
   service delivery, 168–69  
   service standards, 171  
   supervision, 170  
 transcranial direct current stimulation (tDCS), 8–9  
 transcranial magnetic stimulation (TMS). *See* repetitive TMS (rTMS)  
 traumatic brain injury (TBI), 104  
 trazodone, 226  
 treatment-resistant depression, 28, 131  
   ketamine effect on, 149  
 treatment-resistant  
   schizophrenia, 76, 81  
   augmentation strategy, 4  
 tricyclic antidepressants (TCAs), 221, 226  
 tryptophan depletion, 18  
 UK, ECT usage, 1  
 ultrabrief pulse (UBP) ECT, 26, 191  
 unilateral ECT, 190  
   catatonia, 92  
   cognitive side effects, 115  
   depression, 29  
   electrode placement, 78  
   mania, 34  
   right vs. left, 190  
   vs. bilateral, 190  
   vs. bilateral in depression, 3, 15, 25  
 vagus nerve stimulation (VNS), 11, 140–43  
   depression, 143  
   outcome studies, 142–43  
   technical aspects, 141–42  
 valproate, 17, 35  
 valvular heart disease, 249  
 venlafaxine, 24, 44, 194, 226  
 warfarin, 248  
 WHO checklist for ECT treatment, 178, 187  
 written consent, 255  
 xanthines, 194  
 Young Mania Rating Scale (YMRS) scores, 34